RxDoctor Payments Data

Jessica Kovolenko

Family · Sykesville, MDNPI 1922480029

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,352in general payments, 2019–2025

Across 286 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$592
  • Novo Nordisk$562
  • Corium, LLC$346
  • Ironshore Pharmaceuticals Inc.$339
  • AbbVie$328
  • AstraZeneca$222
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,29899%
  • Other$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,352 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland →

Medicare billing

Part B allowed, 2024
$8,015
Medicare patients
36
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Escitalopram Oxalate15$475
Lisinopril26$311
Rosuvastatin Calcium19$303
Levothyroxine Sodium17$226
Atorvastatin Calcium23$208
Zolpidem Tartrate13$173
Losartan Potassium16$115

Paid to pharmacies, not to this prescriber.

Other family in Sykesville

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →